Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo

Journal of Medicinal Chemistry

Volumn 51, Issue 24, 2008, Pages 7915-7920

  Thoma, Gebhard ^a   Streiff, Markus B ^a   Kovarik, Jiri ^a   Glickman, Fraser ^a   Wagner, Trixie ^a   Beerli, Christian ^a   Zerwes, Hans Günter ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; GLYCOPROTEIN GP 120; PLERIXAFOR; PSEUDOTHIOUREA; STROMAL CELL DERIVED FACTOR 1; THIOUREA DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CALCIUM MOBILIZATION; CELL MIGRATION; CHEMOTAXIS; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG POTENCY; HEMATOPOIESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MAXIMUM PLASMA CONCENTRATION; METASTASIS; NONHUMAN; RAT; TARGET CELL; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRUS ENVELOPE;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CHEMOKINE CXCL12; CHEMOKINES; DRUG DESIGN; HIV ENVELOPE PROTEIN GP120; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL; RATS; RECEPTORS, CXCR4; T-LYMPHOCYTES; THIOUREA;

EID: 58149089159     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801065q     Document Type: Article

References (41)

1. (a) Moser, B.; Loetscher, P. Lymphocyte traffic control by chemokines. Nat. Immunol. 2001, 2, 123-128.
2. (b) Murphy, P. M.; Baggiolini, M.; Charo, I. F.; Hebert, C. A.; Horuk, R.; Matsushima, K.; Miller, L. H.; Oppenheim, J. J.; Power, C. A. International Union of Pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 2000, 52, 145-176.
3. (c) Hamada, T.; Tashiro, K.; Tada, H.; Inazawa, J.; Shirozu, M.; Shibahara, K.; Nakamura, T.; Martina, N.; Nakano, T.; Honjo, T. Isolation and characterization of novel secretory protein, stromal cell-derived factor-2 (SDF-1) using the signal sequence trap-method. Gene 1996, 176, 211-214.
4. MIF is being discussed as an additional CXCR4 ligand. Bernhagen, J.; Krohn, R.; Lue, H.; Gregory, J. L.; Zernecke, A.; Koenen, R. R.; Dewor, M.; Georgiev, I.; Schober, A.; Leng, L.; Kooistra, T.; Fingerle-Rowson, G.; Ghezzi, P.; Kleemann, R.; McColl, S. R.; Bucala, R.; Hickey, M. J.; Weber, C. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat. Med. 2007, 13, 587-596.
5. (a) Campbell, D. J.; Kim, C. H.; Butcher, E. Chemokines in the systemic organization of immunity. Immunol. Rev. 2003, 195, 58-71.
6. (b) Broxmeyer, H. E.; Christopherson, K. W., II. Stromal cell derived factor-1/CXCL12, CXCR4, and CD26 in the mobilization and homing of hematopoietic stem and progenitor cells. Cur. Med. Chem.: Anti-Inflammatory Anti-Allergy Agents 2004, 3, 303-311.
7. (c) Bleul, C. C.; Wu, L.; Hoxie, J. A.; Springer, T. A.; Mackay, C. R. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 1925-1930.
8. (a) Knaut, H.; Werz, C.; Geisler, R.; Nusslein-Volhard, C. A zebrafish homologue of the chemokine receptor CXCR4 is a germ-cell guidance receptor. Nature 2003, 421, 279-282.
9. (b) Doitsidou, M.; Reichman-Fried, M.; Stebler, J.; Koprunner, M.; Dorries, J.; Meyer, D.; Esguerra, C. V.; Leung, T.; Raz, E. Guidance of primordial germ cell migration by the chemokine SDF-1. Cell 2002, 111, 647-659.
10. Zou, Y. R.; Kottmann, A. H.; Kuroda, M.; Taniuchi, I.; Littman, D. R. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998, 393, 595-599.
11. (a) Murphy, P. M. Chemokines and the molecular basis of cancer metastasis. N. Engl. J. Med. 2001, 345, 833-835.
12. (b) Staller, P.; Sulitkova, J.; Lisztwan, J.; Moch, H.; Oakeley, E. J.; Krek, W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature, 2003, 425, 307-311.
13. (c) Grunewald, M.; Avraham, I.; Dor, Y.; Bachar-Lustig, E.; Itin, A.; Yung, S.; Chimenti, S.; Landsman, L.; Abramovitch, R.; Keshet, E. VEGF-induced adult neovascularization: Recruitment, retention, and role of accessory cells. Cell 2006, 124, 175-189.
14. (a) Este, Jose, A. Virus entry as a target for anti-HIV intervention. Curr. Med. Chem. 2003, 10, 1617-1632.
15. (b) Xiang, J.; George, S. L.; Wunschmann, S.; Chang, Q.; Klinzman, D.; Stapleton, J. T. Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1α, MIP-1β, and SDF-1. Lancet 2004, 363, 2040-2046.
16. (a) Loetscher, P.; Gong, J. W.; Dewald, B.; Baggiolini, M.; Clark-Lewis, I. N-terminal peptides of stromal cell derived factor-1 with CXC chemokine receptor 4 agonist and antagonist activities. J. Biol. Chem. 1998, 273, 22279-22283.
17. (b) Tudan, C.; Willick, G. E.; Chahal, S.; Arab, L.; Law, P.; Salari, H.; Merzouk, A. C-terminal cyclization of an SDF-1 small peptide analogue dramatically increases receptor affinity and activation of the CXCR4 receptor. J. Med. Chem. 2002, 45, 2024-2031.
18. (a) Bridger, G. J.; Skerlj, R. T.; Thornton, D.; Padmanabhan, S.; Martellucci, S. A.; Henson, G. W.; Abrams, M. J.; Yamamoto, N.; De Vreese, K.; Pauwels, R; De Clercq, E. Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication. Effects of macrocyclic ring size and substituents on the aromatic linker. J. Med. Chem. 1995, 38, 366-378.
19. (b) Joao, H. C.; De Vreese, K.; Pauwels, R.; De Clercq, E.; Henson, G. W.; Bridger, G. J. Quantitative structural activity relationship study of bis-tetraazacyclic compounds. A novel series of HIV-1 and HIV-2 inhibitors. J. Med. Chem. 1995, 38, 3865-3873.
20. (c) Bridger, G. J.; Skerlj, R. T.; Padmanabhan, S.; Martellucci, S. A.; Henson, G. W.; Struyf, S.; Witvrouw, M.; Schols, D.; De Clercq, E. Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4. J. Med. Chem. 1999, 42, 3971-3981.
21. (d) Valks, G. C.; McRobbie, G.; Lewis, E. A.; Hubin, T. J.; Hunter, T. M.; Sadler, P. J.; Pannecouque, C.; De Clercq, E.; Archibald, S. J. Configurationally Restricted Bismacrocyclic CXCR4 Receptor Antagonists. J. Med. Chem. 2006, 49, 6162-6165.
22. (e) Zhan, W.; Liang, Z.; Zhu, A.; Kurtkaya, S.; Shim, H.; Snyder, J. P.; Dennis, C.; Liotta, D. C. Discovery of Small Molecule CXCR4 Antagonists. J. Med. Chem. 2007, 50, 5655-5664.
23. (a) Tamamura, H.; Xu, Y.; Hattori, T.; Zhang, X.; Arakaki, R.; Kanbara, K.; Omagari, A.; Otaka, A.; Ibuka, T.; Yamamoto, N.; Nakashima, H.; Fujii, N. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem. Biophys. Res. Commun. 1998, 253, 877-882.
24. (b) Tamamura, H.; Omagari, A.; Oishi, S.; Kanamoto, T.; Yamamoto, N.; Peiper, S. C.; Nakashima, H.; Otaka, A.; Fujii, N. Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes. Bioorg. Med. Chem. Lett. 2000, 10, 2633-2637.
25. (c) Tamamura, H.; Sugioka, M.; Odagaki, Y.; Omagari, A.; Kan, Y.; Oishi, S.; Nakashima, H.; Yamamoto, N.; Peiper, S. C.; Hamanaka, N.; Otaka, A.; Fujii, N. Conformational study of a highly specific CXCR4 inhibitor, T140, disclosing the close proximity of its intrinsic pharmacophores associated with strong anti-HIV activity. Bioorg. Med. Chem. Lett. 2001, 11, 359-362.
26. (d) Tamamura, H.; Fujii, N. The therapeutic potential of CXCR4 antagonists in the treatment of HIV infection, cancer metastasis and rheumatoid arthritis. Expert. Opin. Ther. Targets 2005, 9, 1267-1282.
27. (a) Fujii, N.; Oishi, S.; Hiramatsu, K.; Araki, T.; Ueda, S.; Tamamura, H.; Otaka, A.; Kusano, S.; Terakubo, S.; Nakashima, H.; Broach, J. A.; Trent, J. O.; Wang, Z.; Peiper, S. C. Molecular-size reduction of a potent CXCR4-chemokine antagonist using orthogonal combination of conformation- and sequence-based libraries. Angew. Chem., Int. Ed. 2003, 42, 3251-3253.
28. (b) Tamamura, H.; Araki, T.; Ueda, S.; Wang, Z.; Oishi, S.; Esaka, A.; Trent, J. O.; Nakashima, H.; Yamamoto, N.; Peiper, S. C.; Akira Otaka, A.; Fujii, N. Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds. J. Med. Chem. 2005, 48, 3280-3290.
29. (c) Tamamura, H.; Hiramatsu, K.; Ueda, S.; Wang, Z.; Kusano, S.; Terakubo, S.; Trent, J. O.; Peiper, S. C.; Yamamoto, N.; Nakashima, H.; Otaka, A.; Fujii, N. Stereoselective synthesis of [L-Arg-L/D-3-(2-naphthyl)alanine]-type (E)-alkene dipeptide isosteres and its application to the synthesis and biological evaluation of pseudopeptide analogues of the CXCR4 antagonist FC131. J. Med. Chem. 2005, 48, 380-391.
30. (d) Niida, A.; Tanigaki, H.; Inokuchi, E.; Sasaki, Y.; Oishi, S.; Ohno, H.; Tamamura, H.; Wang, Z.; Peiper, S. C.; Kitaura, K.; Otaka, A.; Fujii, N. Stereoselective Synthesis of 3,6-Disubstituted-3,6-dihydropyridin-2-ones as Potential Diketopiperazine Mimetics Using Organocopper-Mediated anti-SN2′ Reactions and Their Use in the Preparation of Low-Molecule CXCR4 Antagonists. J. Org. Chem. 2006, 71, 3942-3951.
31. (e) Ueda, S.; Oishi, S.; Wang, Z.; Araki, T.; Tamamura, H.; Cluzeau, J.; Ohno, H.; Kusano, S.; Nakashima, H.; Trent, J. O.; Peiper, S. C.; Fujii, N. Structure-Activity Relationships of Cyclic Peptide-Based Chemokine Receptor CXCR4 Antagonists: Disclosing the Importance of Side-Chain and Backbone Functionalities. J. Med. Chem. 2007, 50, 192-198.
32. (f) Tamamura, H.; Tsutsumi, H.; Masuno, H.; Fujii, N. Development of Low Molecular Weight CXCR4 Antagonists by Exploratory Structural Tuning of Cyclic Tetra- and Pentapeptide-Scaffolds Towards the Treatment of HIV Infection, Cancer Metastasis and Rheumatoid Arthritis. Cur. Med. Chem. 2007, 14, 93-102.
33. (g) DeMarco, S. J.; Henze, H.; Lederer, A.; Moehle, K.; Mukherjee, R.; Romagnoli, B.; Robinson, J. A.; Brianza, F.; Gombert, F. O.; Lociuro, S.; Ludin, C.; Vrijbloed, J. W.; Zumbrunn, J.; Obrecht, J.-P.; Obrecht, D.; Brondani, V.; Hamy, F.; Klimkait, T. Discovery of novel, highly potent and selective β-hairpin mimetic CXCR4 inhibitors with excellent anti-HIV activity and pharmacokinetic profiles. Bioorg. Med. Chem. 2006, 14, 8396-8404.
34. (a) Datema, R.; Rabib, L.; Hincenbergs, M.; Moreno, M. B.; Warren, S.; Linquist, V; Rosenwirth, B.; Seifert, J.; McCune, J. M. Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry. Antimicrob. Agents Chemother. 1996, 40, 750-754.
35. (b) Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery 1997, 23, 3-15.
36. Bigg, D. C. Thiazole derivatives and intermediates. Patent EP 19790613, 1979.
37. Park, Y. J.; Suh, K. H.; Kang, E. C.; Yoon, H. S.; Kim, Y. H.; Kang, D. P.; Chang, M. S. Synthesis and biological activity of the new benzimidazole derivatives having a thiazolo[3,2-a]benzimidazole moiety. Korean J. Med. Chem. 1993, 3, 124-129.
38. Spek, A. L. PLATON, a Multi-Purpose Crystallographic Tool; Utrecht University: Utrecht, The Netherlands, http://www.cryst.chem. uu.nl/platon.
39. Egger, G.; Burda, A.; Glasner, A. A simple method for measuring the F-actin content of human polymorphonuclear leukocytes in whole blood. Virchows Arch. 2001, 438, 394-397.
40. (a) Trent, J. O.; Wang, Z.; Murray, J. L.; Shao, W.; Tamamura, H; Fujii, N.; Peiper, S. C. Lipid bilayer simulations of CXCR4 with inverse agonists and weak partial agonists. J. Biol. Chem. 2003, 278, 47136-47144.
41. (b) Dong, C.-Z.; Kumar, S.; Choi, W.-T.; Madani, N.; Tian, S.; An, J.; Sodroski, J. G.; Huang, Z. Different stereochemical requirements for CXCR4 binding and signaling functions as revealed by an anti-HIV, D-amino acid-containing SMM-chemokine ligand. J. Med. Chem. 2005, 48, 7923-7924.